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Abstract
The gene FKBP5 codes for FKBP51, a co-chaperone protein of the Hsp90 complex that increases with age. Through its
association with Hsp90, FKBP51 regulates the glucocorticoid receptor (GR). Single nucleotide polymorphisms (SNPs) in the
FKBP5 gene associate with increased recurrence of depressive episodes, increased susceptibility to post-traumatic stress
disorder, bipolar disorder, attempt of suicide, and major depressive disorder in HIV patients. Variation in one of these SNPs
correlates with increased levels of FKBP51. FKBP51 is also increased in HIV patients. Moreover, increases in FKBP51 in the
amygdala produce an anxiety phenotype in mice. Therefore, we tested the behavioral consequences of FKBP5 deletion in
aged mice. Similar to that of naı ¨ve animals treated with classical antidepressants FKBP52/2 mice showed antidepressant
behavior without affecting cognition and other basic motor functions. Reduced corticosterone levels following stress
accompanied these observed effects on depression. Age-dependent anxiety was also modulated by FKBP5 deletion.
Therefore, drug discovery efforts focused on depleting FKBP51 levels may yield novel antidepressant therapies.
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Introduction
Genes regulating the hypothalamus-pituitary-adrenal (HPA)
axis are associated with susceptibility to depression as well as
antidepressant efficacy [1,2,3]. The HPA axis has a well-
characterized role as a regulator of the neuroendocrine stress
response [4]. Its activation leads to the production of glucocor-
ticoids in the adrenal axis, of which the major constituent in
humans is cortisol and in rodents is corticosterone. Over the past
decade, genome wide association studies for single nucleotide
polymorphisms (SNPs) revealed significant associations between
susceptibility to depressive episodes and variants in both the
NR3C1, that encodes the glucocorticoid receptor (GR), and
FKBP5, that encodes a GR binding protein thought to attenuate
GR activity [2,5]. While most studies have focused on the variants
in GR because of its role as a transcriptional regulator [6], the
involvement of FKBP5 and its gene product, FKBP51, have
received little attention. This is largely due to uncertainty about
how to approach this relatively unknown protein. In fact, it
remains to be proven whether FKBP51 is a valid therapeutic
target for treating depression, despite its clear genetic link.
Since the initial discovery of the association between FKBP5
SNPs and depression, other psychiatric disorders have been found
to be associated with FKBP5 SNPs including PTSD [7], bipolar
disorder [8], anxiety [9], peritraumatic dissociation [10], and
major depression in HIV patients [11]. The TT variant of the
rs1360780 SNP was associated with both an increased incidence of
depressive episodes throughout a carrier’s lifetime, and increased
sensitivity to common neurotransmitter-based anti-depressants [2].
Interestingly, individuals with the rs1360780 TT SNP had
significantly higher FKBP51 protein levels in their lymphocytes.
FKBP51 levels are also elevated in patients with HIV infection,
perhaps playing a role in the depression that commonly occurs
with chronic highly active antiretroviral therapies (HAART) [12].
Recently, stress was shown to induce neuropsin activity in the
amygdala, inducing anxiety in mice through an FKBP51-
dependent mechanism [13]. How FKBP51 directly modulates
GR has been investigated in vitro. In these systems, upregulation of
FKBP51 decreases the affinity of GR for its substrate. This in turn
decreases the amount of GR that becomes transcriptionally active
[9]. In new world monkeys a naturally occurring glucocorticoid
resistance has been attributed to higher than normal levels of
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24840FKBP51. However, reduced GR activity in a transgenic mouse
model of FKBP51 overexpression has never been shown [14,15].
While the causes of major depressive disorders are unknown,
there is an emerging genetic diathesis forits occurrencewithingenes
regulating the HPA axis; however few animal models have been
developed or utilized for aetiologic validation studies. Genetic
variation in FKBP51 appears to be one factor that facilitates liability
to anxiety and mood disorders. Thus, the goal of this study was to
determine whether decreasing FKBP51 expression could make
mice less susceptible to inducible ‘‘depression-like’’ states through a
corticosterone-dependent mechanism in vivo in well established
models with high predictive value [16]. Indeed, aged FKBP5-
deficient mice were resistant to stress-induced depressive-like
behavior. Moreover, despite robust hippocampal and forebrain
expression patterns, deletion of FKBP5 did not result in cognitive
impairment or other behavioral abnormalities. Circulating levels of
corticosterone inthesameFKBP52/2mice werealsoreducedafter
stress, confirming the proposed mechanism previously described
[9]. These data suggest that not only is FKBP51 a valid therapeutic
target, but targeting this protein may also have minimal
consequences for other behavioral characteristics.
Results
FKBP52/2 mice
FKBP52/2 mice were used to determine the effect of gene
deletion on behavior. The mice contain a b-galactosidase reporter
cassette, which expresses wherever the FKBP5 gene is normally
expressed. To confirm gene knockout and establish cerebral
distribution of FKBP51, tissue from 5.5 and 20-month-old
FKBP52/2 mice was stained using an X-gal kit that produces a
blue product when b-galactosidase is present. An age-dependent
increase in b-gal expression was observed particularly in the upper
cortical layers of the forebrain (Figure 1A). This was consistent
with the age-dependent increase in FKBP51 expression that had
been previously reported in normal mice [17]. To confirm the
absence of FKBP51 protein, whole brain homogenates were
analyzed by immunoblot and probed using an FKBP51 antibody.
No detectable FKBP51 was observed (Figure 1B). To verify that
FKBP51 mRNA was absent, oligo d(T) RT-PCR was performed
using reverse transcriptase to produce cDNA. No FKBP5 PCR
product was detected in the FKBP52/2 mice, confirming that no
FKBP51 mRNA was present (Figure 1C).
Antidepressive behavior in FKBP52/2 mice
FKBP52/2 mice aged 17–20 months were submitted to two
behavioral models of depressive-like activity; the classical forced
swim test (FST) and the tail suspension test (TST) [18,19]. Results
from these tests are based on the total time spent immobile over a
6-minute period, interpreted as despair. These tests are typical for
assessing antidepressant efficacy [18]. Aged FKBP52/2 mice
displayed a shorter immobility time than their wildtype counter-
parts (Figure 2A–2B). The weight, activity, and physical fitness of
the mice were evaluated to account for possible confounding
factors, but these variables did not contribute to the effect
(Figure 2C–2E).
Effect of FKBP52/2 on corticosterone production
Stress causes increased levels of cortisol in humans and
depressed patients have higher-than-normal levels of cortisol in
the blood [20]. The dexamethasone-corticotropin releasing
hormone (DEX-CRH) test, a commonly used tool to detect
HPA system changes, has been used to link depressive behavior
with glucocorticoid receptor (GR) insensitivity [21]. To determine if
FKBP5 deletion was altering glucocorticoid levels, circulating
corticosterone levels were assessed in the same aged cohort of
FKBP52/2 mice that were used for behavioral analyses. Early
morning blood draws were collected from both FKBP52/2 and
wildtype littermates before and 30 minutes after being placed in a
restrainer for 10 minutes. Levels of basal corticosterone were
predictably low, consistent with previous reports showing low levels
of corticosterone production in the earliest part of the murine
diurnal cycle (Figure 3) [22]. After stress corticosterone levels rose in
both wildtype and FKBP52/2 mice, but this induction was
attenuated in the FKBP52/2 mice. These findings suggest that the
Figure 1. Distribution and confirmation of gene knockout. (A) Representative images of b-gal staining in horizontal brain slices of 5.5 and 20
month old FKBP52/2 mice. (B) Western blot analysis of 20-month old wildtype and FKBP52/2 whole brain homogenates. (C) FKBP5 primer-specific
PCR of cDNA synthesized from brain-isolated mRNA by reverse transcription.
doi:10.1371/journal.pone.0024840.g001
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which decreases HPA-axis activity and corticosterone levels,
improving resilience to depressive-like behavior.
Characterization of anxious behavior in the FKBP52/2
model
Brain-specific knockout of GR in mice reduces anxiety [23].
Also, FKBP51 expression was recently correlated to anxious
behavior [13]. Based on this and the novel link now established
between FKBP51, GR activity and glucocorticoid production, the
effects of FKBP5 deletion on anxiety were tested. The longitudinal
impact of FKBP5 deletion on anxiety was assessed in mice aged 11–
14 months and then again in the same mice aged 18–22 months
using the elevated plus maze (EPM). A repeated measures two-way
analysis of variance was conductedto examine the effect of time and
genotype on anxiety. The behavioral correlates of anxiety in the
EPM were significantly affected by age, and this change depended
on the genotype at FKBP5 as reflected by a significant age*genotype
interaction, (Figure 4A–4B). Indeed, in wildtype mice behavioral
correlates of anxiety decreased with age, whereas they appeared to
increase in FKBP52/2 mice. To further examine whether anxiety
wasindeed being modified in thesemice, the 18–22 month-old mice
Figure 2. FKBP52/2 mice display resistance to depression inducing stimulus. (A) Total time immobile in the tail suspension test; *p,0.05,
t=2.870, df=16. (B) Total time immobile in the forced swim test; **p,0.01, t=2.982, df=16. (C) No significant difference was observed between
mass measurements of groups. (D) Latency to fall from a gradually accelerating rotorod apparatus displays no difference between groups. (E) Activity
levels in the open field display no differences between groups.
doi:10.1371/journal.pone.0024840.g002
Figure 3. Effects of FKBP52/2 on corticosterone production.
Levels of corticosterone in serum right before a 10-minute tube
restraint and 30 minute after (wt n=5, FKBP52/2 n=6); interaction
F(1,18)=11.54, **p,0.01; genotype F(1,18)=11.72, **p,0.01; stress
F(1,18)=40.5, ***p,0.0001; Bonferroni multiple comparisons wt vs
FKBP52/2 stress, t=4.82, ***p,0.001.
doi:10.1371/journal.pone.0024840.g003
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another standard measure of anxiety. The mice were allowed to
explore between a well-lit and unprotected area and a dark covered
area that the mice had access to through a small opening. Normal
mice typically move to the dark chamber. The light-dark maze did
not reveal any statistical differences between the groups (Figure 4C–
4D). These data suggest that suppression of FKBP51 may have a
differential effect on anxiety depending on the developmental stage;
however, theeffectisnotpervasive enough to manifestitself through
several indices of anxiety.
Memory and general behavioral characterization of
FKBP52/2 mice
Untoward consequences of FKBP51 ablation were a distinct
possibility given the ubiquitous expression of FKBP51 throughout
the brain. Given the high levels of expression of FKBP5 in the
hippocampus (Figure 1A) memory formation was assessed.
Therefore, short-term memory in the FKBP52/2 mice was
tested with the use of the novel object recognition and Y-maze
paradigms. Both tests are performed in a short period of time to
capture the working memory ability of the mice. Neither test
showed statistically significant differences between FKBP52/2
and wildtype littermates (Figure 5A–5B). Long-term spatial
memory function was then tested using the Morris water maze
(MWM). Memory retention was tested 24 hours after the training
was completed. The training phase of the MWM displayed that
wildtype and FKBP52/2 mice were equally capable of learning
the location of a hidden platform (Figure 5C). Moreover wildtype
and FKBP52/2 mice displayed an equivalent capacity to locate
the hidden platform 24 hours after training (Figure 5D).
The amygdala controls emotional learning in the brain and
FKBP5 expression can be upregulated by GR activation [24]. As a
consequence, function of the amygdala could be affected by
FKBP5 deletion. To test the impact of FKBP52/2 on emotionally
derived memory function, a fear-conditioning paradigm was
employed. In this test, a tone played for 30 seconds is followed
by a small foot shock. Thus the animal learns to associate the tone
with the shock. The amygdala-associated fear response caused by
the tone is able to bypass the hippocampus once the association is
made, allowing for assessment of emotionally driven memory
formation. Surprisingly, no differences between wildtype and
FKBP52/2 mice were observed in either contextual (environ-
mentally-based) or cued (tone-based) fear conditioning paradigms
(Figure 5E–5G). These findings suggest that neither spatially nor
emotionally driven long-term memory is affected by FKBP5
deletion. In addition to these learning and memory tasks, no
observable differences between wildtype and FKBP52/2 mice
were noted in tasks designed to assess activity, motor performance,
motor coordination, motor learning, hearing, or prepulse
inhibition, which measures startle response inhibition (Figure 6).
Discussion
Major depression is a devastating disease with a course that is
frequently chronic or recurrent and affects millions of people.
Figure 4. Age-associated changes in anxious behavior in FKBP52/2 mice. (A) Time spent in closed arms of the EPM (n=8 for each group);
interaction F(1,14)=4.59, p=0.0502; genotype F(1,14)=0.14, p=0.713; time F(1,14)=8.38, *p,0.05. (B) Time spent in open arms of the EPM (n=8 for
each group); interaction F(1,14)=8.30, *p,0.05; genotype F(1,14)=0.0, p=0.999; time F(1,14)=6.33, *p,0.05. (C) Time spent in the areas of the dark-
light chamber (wt n=8, FKBP52/2 n=8); interaction F(1,28)=6.13, *p,0.05; genotype F(1,28)=0, p=0.999; amount of light in chamber
F(1,28)=57.9, ***p,0.0001. (D) Number of entries into the areas of the dark-light chamber (wt n=8, FKBP52/2 n=8); interaction F(1,26)=0.01,
p=0.933; genotype F(1,26)=5.82, *p,0.05; amount of light in chamber F(1,26)=0.02, p=0.879.
doi:10.1371/journal.pone.0024840.g004
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gene is associated with depression and several other mood and
anxiety disorders. And although in vitro data suggests the possibility
of a causal relationship between FKBP5 expression levels and
depression, this has never been tested in vivo. Here we show for the
first time that ablation of FKBP5 in mice led to reduced immobility
in two behavioral models that are routinely used to assess anti-
depressant efficacy. This behavioral effect coincided with attenu-
ation of corticosterone production after a stressful episode.
Moreover, no defects in locomotion, somato-sensation or learning
Figure 5. Deletion of the FKBP5 gene does not alter learning and memory despite robust expression of FKBP5 in the hippocampus.
(A) Discrimination index between familiar and novel object in the novel object recognition test. (B) Percent of spontaneous alternation shows no
difference between the groups. (C) Learning of the location of the hidden platform in the MWM (interaction F(5,80)=0.14, p=0.98; genotype
F(1,16)=0.0, p=0.98; time F(5,80)=12.71, p,0.0001). (D) Percent time spent in quadrant during the probe trial of MWM. (E) Software generated heat
plot representing amount of time spent in an area. (F) Percent freezing during training portion of fear conditioning; interaction F(6,90)=4.1,
**p=0.001; genotype F(1,15)=5.66, *p=0.031; time F(6,90)=79.89, ***p,0.0001; Bonferroni multiple comparisons wt vs FKBP52/2 at 240 s, t=2.42,
***p,0.001. (G) Percent freezing during contextual exposure to fear-conditioning chamber. (H) Percent freezing during the cued fear-conditioning
test; interaction F(1,30)=0.05, p=0.828; genotype F(1,30)=0.25, p=0.624; tone F(1,30)=55.75, ***p,0.0001.
doi:10.1371/journal.pone.0024840.g005
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FKBP51 levels may be highly efficacious as next generation anti-
depressants. Furthermore, because FKBP51 ablation results in
reduced anxiety-like behavior in mice [13], we provide experimental
supportforthenotionthatgenetically-drivenvariationsinexpression
of FKBP51 may underlie susceptibility to anxiety and mood
disorders, as suggested by association studies in humans [2,9].
FKBP51 is a peptidyl-prolyl cis-trans isomerase (PPIase) enzyme
that also associates with the chaperone Hsp90 and is distributed
ubiquitously throughout the brain. This isomerase activity is
thought to be important for structural rearrangements and
phosphorylation dynamics of client proteins bound by Hsp90.
Several diseases in addition to psychiatric conditions have
implicated FKBP51 as having a role in their pathogenesis. These
include prostate cancer [25], and neurodegenerative diseases,
specifically tauopathies [17]. In fact, these effects on tau may
somehow be tied to the manifestation of these psychiatric
conditions. Indeed, depleting FKBP51 levels was shown to also
Figure 6. Behavioral characterization of FKBP52/2 mice. (A) Distance traveled in the open field test. (B) Assessment of motor learning from
comparison between the average of all four trials of rotorod from day one with those of day two; interaction F(1,16)=1.28, p=.275; genotype
F(1,16)=1.37, p=0.259; time F(1,16)=80.3, ***p,0.0001. (C) Latency to fall from the rotorod apparatus; interacton F(7,112)=1.28, p=0.267;
genotype F(1,16)=1.37, p=0.259; time F(7,112)=17.97, ***p,0.0001. (D) Percent inhibition of startle response by increasing prepulse intensity;
interaction F(4,70)=0.61, p=0.656; genotype F(1,70)=0.33,p=0.565; prepulse intensity F(4,70)=3.07, *p,0.05. (E) Comparison of no pulse (no tone)
with a 120 dB pulse (tone) to test hearing; interaction F(1,32)=0.11, p=0.74; genotype F(1,32)=0.16, p=0.694; pulse F(1,32)=147.58, ***p,0.0001.
doi:10.1371/journal.pone.0024840.g006
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to increased stability of phosphorylated tau. Thus it is certainly
possible that FKBP51 is involved in Alzheimer’s disease
progression, since one of its earliest clinical features is depression.
More recently, the extracellular protease neuropsin was shown to
mediate anxiety-like behavior via an FKBP51 dependent mech-
anism [13]. Thus, an important role for FKBP51 in maintaining
proper brain function is emerging. Its relationship with major
depressive disorder in HIV, bipolar disorder and possibly anxiety
and Alzheimer’s disease further underlie its significance.
Current treatment for depression includes the use of medica-
tions that extend the amount of time neurotransmitters are present
in the synaptic cleft including serotonin, norepinephrine, and
dopamine. It is estimated that 60–70% of patients reach remission
with the use of anti-depressant drugs [26]. These low rates of
efficacy have prompted research into other potential therapeutic
targets in the HPA axis, particularly GR. However, there are
many different isoforms of GR, making selective targeting with
compounds challenging. Therefore, the results presented here
show that FKBP51 may be the most appropriate target for treating
depression via the modulation of the HPA axis in terms of its risk/
benefit equation and potential therapeutic window. Also, and most
noteworthy, because FKBP51 may act on the genetic liability to
abnormal mood and anxiety states, it may provide a much needed
treatment tool for secondary prophylaxis of depression recurrence
and relapse.
Materials and Methods
Generation of FKBP52/2 mice
The mice have been generated as published previously [27].
Briefly, by PCR screening the 129SvJ mouse BAC library
(Genome Systems, St. Louis, MO), bacterial artificial chromosome
(BAC) clones that contained genomic regions for FKBP5 were
isolated. Restriction fragments were subcloned into pBluescript
(pBS; Stratagene, La Jolla, CA) or pZero (Invitrogen, Carlsbad,
CA) cloning vectors. The PCR products were amplified from the
BAC clones and were then used to construct a targeting vector in
the pPGKneo vector (a generous gift of James Lee, Mayo Clinic
Scottsdale). The targeting vector contained a beta-galactosidase/
neomycin cassette flanked by regions homologous to the FKBP5
gene. Due to the size of the protein it is more practical to partially
delete the gene. Thus, when the targeting vector integrates into the
chromosome through homologous recombination it removes all of
exon 2, which is the first coding exon. Since the only deleted
portion of the gene is exon 2 the expression of the beta-
galactosidase protein is dependent on the FKBP5 promoter and
transcription machinery and expresses in frame with the initiation
codon. ES cells were isolated from the 129SvJ mouse and cultured
in Knockout DMEM media (Invitrogen) supplemented with 10%
FBS, penicillin/streptomycin, essential amino acids, and ESGRO
(103 U/ml; Chemicon, Temecula, CA) with irradiated embryonic
fibroblast feeder cells. The ES cells were then electroporated at
0.2 kV, 950 mF (Gene Pulser II; Bio-Rad, Hercules, CA) with
linearized targeting vectors and selected with G418. DNA from
G418-resistant clones was isolated for Southern blot analysis. A
DNA probe was used to distinguish PstI restriction fragments from
wildtype allele (,7.5 kb) and targeting vector (,10 kb). Appro-
priate homologous recombination in ES cell clones was confirmed
by PCR using primers complementary to sequences within the
neomycin cassette and to 39 FKBP5 sequences downstream from
the recombination site. ES cell clones containing the targeting
vector were injected into C57BL/6 blastocysts and implanted into
pseudopregnant 129SvJ females. Chimeric offspring were identi-
fied by coat patterns and mated to C57BL/6 mice to obtain
germline transmission of the targeting vector. For colony
maintenance mice were crossed from C57BL6 onto Swiss-Webster
for purposes of fecundity and genetic diversity to be more
representative of a human population.
Brain Tissue Fractionation and Western Blot Analysis
Brain tissue fractionation and western blot analysis were done as
previously described [28].
PCR
mRNA was isolated and purified from the brain of four wildtype
and four FKBP52/2 mice using RNAeasy kit (QIAGEN,
Valencia, CA). cDNA was synthesized from isolated mRNA by
reverse transcription using Super Script III First-Strand cDNA
Sythesis Kit (Invitrogen, Carlsbad, CA) from 50 ng of isolated
mRNA. PCR was performed with synthesized cDNA and FKBP5
specific primers to confirm presence or absence of FKBP5 gene.
Antibodies
Horseradish peroxidase conjugated secondary antibodies
(Southern Biotech, Birmingham, AL), Glyceraldehyde-3-phos-
phate dehydrogenase antibody (Meridian Life Science, Saco,
ME), Anti-FKBP51 was provided by Drs. David F. Smith and
Marc Cox (Mayo Clinic, Scottsdale, AZ).
Immunohistochemistry
Fixed mouse brains were processed for sectioning as previously
described [29]. b-galactosidase staining was performed using the in
situ b-gal staining kit (Stratagene, La Jolla, CA).
Behavior
N=9 unless otherwise noted. Video tracking software was used
in several tests (ANY-Maze, Stoelting, Illinois).
Open Field
Animals were monitored for 15 min in an open field with video
tracking software.
Rotorod test
Testing started at an initial rotation of 4 rpm accelerating to
40 rpm over 5 min. Mice were tested for 4 trials per day, for 2
consecutive days with a 30-min intertrial interval. Latency to fall
from the rod onto a spring-cushioned lever was measured.
Morris water maze (MWM)
Mice were trained to locate an escape platform hidden beneath
the water (3 centimeter). Each mouse was given 4 trials per day
with an intertrial interval of 1 hour for 6 consecutive days. Each
animal was given 60 seconds to find the platform. Afterwards the
mice were placed on the platform for 30 s. On day 7, mice were
subjected to a trial in which the platform was removed, and had
60 s to search for it.
Associative Fear Conditioning
Two mild foot shocks (0.5 milliamps) were paired with an
auditory conditioned stimulus (CS, white noise, 70 decibels) within
a novel environment. The CS was given for 30 s before each foot
shock (2 s). Twenty-four hours later, the mice were placed in the
chamber and monitored for freezing for 3 min (no shocks or CS).
Immediately after the test, mice were placed into a novel context
for 3 min without CS and then exposed to the CS for 3 min
(cued).
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Mice were placed in a restrainer (Panlab, Barcelona Spain) and
placed inside a sound attenuation chamber. The test consisted of 7
trial types in pseudorandom order: 1) 40 ms, 120 decibels sound
burst (startle); 2–6) 5 different acoustic prepulses 100 ms in length,
a 20 ms duration at 74, 78, 82, 86, and 90 dB; 7) no stimulus for
baseline measurement. The intertrial interval was 15 s. The startle
response peak was measured within a second after the stimulus.
Elevated Plus Maze (EPM)
EPM consisted of 2 open arms facing each other and two
enclosed arms also facing each other. Each arm is attached to the
center platform and elevated 40 centimeters off the floor. The
mouse was placed on the platform and allowed to explore for
5 min. Video tracking software measured movement.
Porsolt forced swim test (FST)
Each mouse was placed in a 45 centimeters high and
20 centimeters diameter clear Plexiglas cylinder filled with room
temperature water to a depth of 12 centimeters for 6 min.
Amount of time spent immobile was recorded.
Tail Suspension Test (TST)
Mice were suspended from their tail for 6 min. Amount of time
spent immobile was recorded.
Novel Object
Mice were placed in an area with two objects similar in scale to
the mouse. Each animal was given 3 acclimation trials of 5 min
with a 5-min intertrial interval. Then one acclimated object was
replaced with a novel object. Animals were given a 5-min
exploratory trial monitored by video recording.
Y-maze
Animals were started at the center of the Y and allowed to
explore for 8 min. Each session was video-monitored. The number
of arm entries was recorded. The percent of spontaneous
alternation was calculated as the number of triads containing
entries into all three arms divided by the maximum possible of
alternations (total number of entries minus 2).
Corticosterone Assay, blood collection and stress
paradigm
The levels of corticosterone were measured using an ELISA kit
(Enzo Life Sciences, Plymouth Meeting, PA). Blood from mice was
collected in the morning one hour after the light cycle began and
30 min after a 10-min tube restraint using the submandibular vein
puncture method.
Statistics
The student’s t-test was used to compare 2 groups. The paired t-
test was used to compare paired observations within 2 groups. The
2-way RMANOVA was used to compare the interaction between
two dependent variables and an independent variable. The
Bonferroni post test was used to correct for multiple testing. All
error bars represent S.EM.
Animal Study Approval
All animal procedures were approved by the University of
South Florida Institutional Animal Care and Use Committee
(IACUC), protocol #R3848.
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